Novel nanosensing platform helps distinguish faulty adeno-associated viral vectors
Researchers have introduced an innovative nanosensing method to assess the properties of viral vectors.
In a collaborative study, a team of researchers from Osaka University, Nagoya University and University of Tokyo (all Japan) have developed a nanosensing platform that can distinguish between defective and functional viral vector particles. The nanosensing platform has the potential to enhance quality control methods of medicinal products that utilize viral vector technology, such as adeno-associated viral (AAV) vectors, which may help reduce potential side effects that result from defective particles.
Researchers have leveraged the physiological properties of viral vectors for developing medicinal products such as vaccines and gene therapies, which have revolutionized the way we approach diseases. Currently, developers use a range of techniques including mass photometry, transmission electron microscopy and analytical ultracentrifugation to assess the quality of AAV vectors during the manufacturing process. However, there are still chances of partial or empty vectors being missed; these defective particles could lead to side effects, highlighting the need for more rigorous quality control procedures.
To tackle this issue, the researchers utilized nanosensing technology to design a sensor that can identify genomic differences at the single-molecule level. They applied a voltage differential to a solution containing AAV vectors and measured the ionic current that flowed through the nanopore opening of the detector. The nanosensing platform can detect when a viral particle passes through the nanopore, illustrated as a spike in the ionic current readout.
New bioactive material promotes cartilage repair
Researchers have developed a new material to promote cartilage repair and long-lasting joint health.
During their analysis, the team observed something interesting – on the readout, the faulty vectors that passed through the nanopore produced ‘signatures’ that were noticeably different from those produced by the bulkier, heavier full-genome vectors, which helped the researchers identify variations between the AAV vectors. To verify their findings, the researchers employed various techniques such as finite-element simulations and theoretical analyses; these findings aligned with their initial observations when identifying individual faulty AAV vectors.
This technique could potentially provide a convenient and cost-effective solution to current methods of AAV vector quality control. By establishing higher quality AAV vectors, researchers hope to reduce both the dose administered to patients and the side effects experienced.
Looking ahead, this nanosensing platform could apply to other viral vector studies, contribute to our understanding of virology and potentially pave a new way for efficacious gene therapies.
“The present work may revolutionize medicine by providing a tool for preparing AAV vectors with ultra-high quality for safe and effective gene therapy,” shared Yuji Tsunekawa (University of Tokyo). “It may be key in the development of production and purification systems for AAV vectors.”
